Sitemap

Prescribing Information and Adverse Event Reporting can be found at the bottom of the page

MAT-GB-2004982 (v5.0) | Date of preparation: May 2023
___________________________________________________________________________________________________________________________________________________________________________

You are about to leave this website.

This link takes you to a third party website. Sanofi Genzyme has no control over the content of the website you are about to access. The terms of usage of the third party website will differ from that of the www.dupixent.co.uk. It is recommended that you carefully read the legal notice, cookies and privacy policy of third party websites before accessing these sites.

By continuing you are acknowledging that you have read this notice.

MAT-IE-2101043(v3.0) | Date of preparation: October 2021

CONTINUE

DUPIXENT is now indicated in children aged 6–11 years¹

As add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by raised EOS and/or raised FeNO

Who are inadequately controlled with medium-to-high dose ICS plus another medicinal product for maintenance treatment

FIND OUT MORE >